Background. Mitochondrial dysfunction plays an important role in the pathogenesis and progression of diabetic nephropathy (DN). We study the relation between urinary and intrarenal mitochondrial deoxyribonucleic acid (mtDNA) levels and renal dysfunction in DN. Methods. We recruited 92 patients with biopsy-proven DN. Urinary sediment, urinary supernatant and intra-renal mtDNA levels were measured and compared with baseline renal biopsy, kidney scarring and renal function decline in the subsequent 24 months. Results. mtDNA could be detected in all urine supernatant, urine sediment and renal biopsy specimens. There was a modest but statistically significant inverse correlation between urinary supernatant and intra-renal mtDNA levels (r ¼ À0.453, P ¼ 0.012). Urinary supernatant mtDNA level had modest but statistically significant correlations, inversely with estimated glomerular filtration rate (r ¼ À0.214, P ¼ 0.04), and positively with interstitial fibrosis (r ¼ 0.300, P ¼ 0.005). Intra-renal mtDNA had significant inverse correlation with interstitial fibrosis (r ¼ À0.537, P ¼ 0.003). However, there was no significant relation between renal function decline and urinary supernatant, urinary sediment or intra-renal mtDNA levels. Conclusions. mtDNA is readily detectable in urinary supernatant and kidney tissue, and their levels correlate with renal function and scarring in DN. Further studies are needed to determine the accuracy of urinary supernatant mtDNA level as a prognostic indicator of DN, as well as its role in other kidney diseases.
I N T R O D U C T I O N
Diabetic nephropathy (DN) is the most common cause of endstage renal disease (ESRD) in the world [1, 2] . In Hong Kong, DN accounts for around 50% of new dialysis patients [3] . With the epidemic of obesity and metabolic syndrome, it is expected that the incidence of DN would continue to increase in the coming decades [4, 5] .
Unfortunately, the underlying mechanism of progressive renal function loss in DN is complicated and remains incompletely understood. Recent studies showed that acquired mitochondrial dysfunction is an important contributing factor in the progression of DN [6, 7] and other chronic kidney diseases (CKD) [8] . Notably, proteinuria caused by a primary insult to the kidney induces oxidative stress on renal tubular cells, resulting in mitochondrial dysfunction [9] [10] [11] , which could lead to cellular damage by reactive oxygen species generation as well as epithelial-mesenchymal transition (EMT) [12, 13] . In experimental models of CKD, aborting mitochondrial dysfunction prevents renal tubular cell EMT and renal fibrosis [9, 14] .
Previous studies showed that damaged mitochondria release their DNA content into the systemic circulation [15, 16] . Cellfree mitochondrial deoxyribonucleic acid (mtDNA) could easily be detected in plasma, and has been explored as the biomarker of various diseases [17] [18] [19] [20] [21] [22] . Since dysfunctioned mitochondria of renal tubular cells also release mtDNA into urine, it is logical to hypothesize that urinary mtDNA level may serve as a biomarker of kidney diseases. A recent study showed that urinary mtDNA level is increased in mice after 10-15 min of ischemia, and the level correlates with the duration of ischemia [23] . In human acute kidney injury (AKI), urinary mtDNA level correlated with the severity of AKI, and was elevated in patients with progressive disease [23, 24] . However, the prognostic role of urinary mtDNA levels in DN has never been studied.
M A T E R I A L S A N D M E T H O D S

Patient selection
This was an observational study. The study was approved by the Clinical Research Ethics Committee of the Chinese University of Hong Kong. All study procedures were in compliance with the Declaration of Helsinki. We studied 92 consecutive patients with Type 2 diabetes mellitus and biopsy-proven DN in our center. After written informed consent, a whole-stream early morning urine specimen was collected for the measurement of mtDNA level. Clinical, biochemical and histopathological data were collected by chart review. Glomerular filtration rate (GFR) was estimated by a standard equation [25] . CKD is defined and staged according to the standard criteria [26] . All patients received baseline angiotensin-converting enzyme inhibitor or angiotensin receptor blocker treatment unless there was clinical contraindication.
Urine and intra-renal mtDNA level All urine specimens were processed immediately after collection according to methods described previously [27] . Briefly, protease inhibitors were added, and then samples were centrifuged at 1000 g to remove cells and cellular debris. Urinary sediment and supernatant specimens were then separated and stored at À80 C until analysis. Urinary mtDNA was isolated and purified from supernatant and sediment by QIAamp DNA Blood Midi Kit (Qiagen Sciences, Germantown, MD, USA) according to the manufacturer's instructions. For intra-renal mtDNA level, frozen tissue from renal biopsy was cut into 2 mm samples for intra-renal mtDNA extraction using QIAamp DNA Mini Kit (Qiagen Sciences) according to the manufacturer's instructions. mtDNA level was measured by digital polymerase chain reaction (PCR) and then adjusted by urinary creatinine level. The chip-based digital PCR platform (QuantStudio 3D digital PCR System, Life Technologies, Carlsbad, CA, USA) was used. The method of quantification of urinary mtDNA has been reported previously [23] . Briefly, a maximum of 3 mL of DNA is mixed with 8 mL of dPCR master mix (2Â), 0.8 mL of mtDNA assay (primers, 150 nM each with MGB TaqMan; probe, 250 nM; both from Life Technologies) and made up to 15 mL. The PCR mix was then loaded on the digital PCR 20K chip using the QuantStudio 3D digital PCR Chip Loader. PCR was performed using the flat-block ProFlex PCR system according to manufacturer instructions. Each digital PCR run was performed with a blank control by adding water in place of template. The PCR condition was as follows: 96 C for 10 min, 40 cycles of 60 C for 2 min and 98 C for 30s, and finally 60 C for 2 min. After the thermal cycling, the chips were imaged using the QuantStudio 3D digital PCR Chip Reader and analyzed by the QuantStudio 3D AnalysisSuite software. Urinary mtDNA levels were normalized by urinary creatinine.
Morphometric study of kidney biopsy
The severity of glomerulosclerosis and interstitial fibrosis was assessed by standard morphometric study [28] . Briefly, Jones' silver staining was performed on 4-mm thick sections of kidney biopsy specimens. Computerized image analysis method was used, with 10 glomeruli and 10 randomly selected tubulointerstitial areas assessed for each patient.
Clinical outcome
All patients were followed for 24 months. The primary endpoints were renal survival and the slope of GFR decline. Events of renal survival included death of any cause, doubling of baseline serum creatinine and need of long-term dialysis. The slope of GFR decline was calculated by the least-square method.
Statistical analysis
Statistical analysis was performed by SPSS for Windows software version 18.0 (SPSS Inc., Chicago, IL, USA). Results was expressed as mean 6 standard deviation unless otherwise specified. Data between groups were compared by unpaired Student's t-test, one way analysis of variance (ANOVA) or Kruskal-Wallis test as appropriate. Relation between urinary mtDNA level and clinical and histological parameters was determined by Spearman's rank correlation coefficient after adjusting for multiple comparison. In addition, patients were divided into tertiles I to III according to their urinary supernatant mtDNA levels (with tertile III the highest level) for analysis. Since the relationship between mtDNA level and renal disease might not be linear, tertile I was further analyzed separately. For the primary endpoint, multivariate linear regression analysis was performed to adjust for clinical confounding factors. For the effect of mtDNA levels on renal survival, Cox regression analysis was performed. A P-value below 0.05 was considered statistically significant. All probabilities were two-tailed.
R E S U L T S
We recruited 92 patients with DN. Their demographic, baseline clinical and biochemical information are summarized in Table 1 . mtDNA could be detected in all urinary supernatant and urine sediment specimens, with average levels 1421.0 6 1827.5 and 286 114.4 6 193 481.0 copies/mL, respectively. There was a modest but statistically significant inverse correlation between urinary supernatant and intra-renal mtDNA levels (r ¼ À0.453, P ¼ 0.012). In contrast, urinary sediment mtDNA level did not correlate with urine supernatant or intra-renal mtDNA level.
Relation with baseline parameters
The relations of urinary and intra-renal mtDNA levels with clinical and pathological parameters are summarized in Table 2 . Urinary supernatant mtDNA level had modest but statistically significant correlations, inversely with estimated GFR (r ¼ À0.214, P ¼ 0.04), and positively with the severity of interstitial fibrosis (r ¼ 0.300, P ¼ 0.005). In contrast, intrarenal mtDNA had significant inverse correlation with the severity of interstitial fibrosis (r ¼ À0.537, P ¼ 0.003). There was no significant correlation between urinary sediment mtDNA level and any clinical or pathological parameter. The correlation between urine supernatant mtDNA level and renal function remained similar after adjusting for urinary creatinine level (details not shown).
Since urinary supernatant mtDNA level had significant correlations with renal function and scarring, patients were divided into tertiles I to III according to their urinary supernatant mtDNA levels (with tertile III being the highest level), and their baseline clinical and demographic data are summarized and compared in Table 1 . When tertile I was analyzed separately, urinary supernatant mtDNA levels significantly correlated with proteinuria (r ¼ 0.397, P ¼ 0.027), but not estimated GFR (r ¼ 0.160, P ¼ 0.4), or the severity of glomerulosclerosis (r ¼ À0.184, P ¼ 0.3) or tubulointerstitial fibrosis (r ¼ 0.038, P ¼ 0.8).
Relation with clinical outcome
All of the patients were followed for 24 months. During this period, 15 patients died, and 19 progressed to dialysis dependent renal failure. The Kaplan-Meier plot of renal survival is shown in Figure 1 . The 2-year renal survival of urinary supernatant mtDNA-level tertiles I, II and III are 64.5%, 67.7% and 56.7%, respectively (log rank test, P ¼ 0.7). Similarly, there was no significant relation between urinary supernatant, urinary sediment or intra-renal mtDNA levels, with or without correction for urinary creatinine level, and renal survival as determined by univariate Cox regression analysis (details not shown).
There was also no significant correlation between the rate of GFR decline and urinary supernatant mtDNA (r ¼ À0.070, P ¼ 0.5), urinary sediment mtDNA (r ¼ À0.163, P ¼ 0.3) or intra-renal mtDNA level (r ¼ À0.215, P ¼ 0.3). When tertile I was analyzed separately, urinary supernatant mtDNA levels had a trend of correlation with the rate of GFR decline (r ¼ À0.321, P ¼ 0.08), a the result did not reach statistical significance.
D I S C U S S I O N
Our results show that mtDNA is easily detectable in the urinary supernatant and sediment, as well as kidney tissue of DN. There is a significant inverse correlation between urinary supernatant and intra-renal mtDNA levels, which suggests that depletion 
Data are analyzed by Spearman's rank correlation coefficient. of intra-renal mitochondria results in increasing of urinary mtDNA levels. Furthermore, both urinary supernatant and intra-renal mtDNA levels had significant correlations with estimated GFR and the severity of interstitial fibrosis, indicating that they are markers of renal scarring in DN. Our observation that reduction in intra-renal mtDNA level correlates with the degree of renal damage is in line with previous studies on mitochondrial dysfunction in DN. Intra-renal oxidative stress plays a critical role in the initiation and progression of diabetic kidney disease [29] . Patients with DN have impaired mitochondrial metabolism compared with diabetic patients without nephropathy [30] . An early manifestation of the DN is the development of kidney hypoxia as a result of altered mitochondrial functions, including altered mitophagy, mitochondrial dynamics, uncoupling and cellular signaling through hypoxia inducible factors and AMP-kinase [31] . Hyperglycemia induces damage to mitochondrial respiration in glomerular mesangial and renal tubular cells [32] . Alteration of mtDNA copy number has been report in the peripheral blood of diabetic patients with atherosclerosis [33] and retinopathy [34] . However, there has been no study on the alteration of intra-renal (or peripheral blood) mtDNA content in DN, and our present study is the first report on tissue-specific alteration in mtDNA content in diabetes.
It is important to realize that the changes of mtDNA may evolve in different stages of renal diseases and the relationship is unlikely to be linear. From the perspective of biomarker development, it would be more meaningful to focus on the early stage of disease. In our cohort, tertile I of urinary supernatant mtDNA level represents a group of patients with mild mitochondrial damage and is therefore analyzed separately. In essence, we found that in this subgroup of patients, urinary supernatant mtDNA level correlated with proteinuria and marginally with the rate of GFR decline, suggesting that supernatant mtDNA level may provide additional prognostic information in patients with early DN. Because of the small sample size, further subgroup analysis was not performed. Nonetheless, further studies that focus on incipient diabetic kidney disease (e.g. patients with microalbuminuria) would be important.
Our work on urinary supernatant mtDNA level represents a novel extrapolation of previous studies on AKI. In AKI following cardiac surgery, urinary mtDNA level predicts renal function recovery [23] . In another study, urinary mtDNA level was found to be a marker of AKI severity, with significant correlation with peak serum creatinine level, duration of hospital stay and probably the need for temporary dialysis [35] . Our present study is the first one that explores the clinical use of urinary supernatant mtDNA level in CKD.
Despite the significant correlation with renal function and scarring, neither urinary supernatant nor intra-renal mtDNA levels correlate with renal survival. The negative result may be caused by the sample size and relatively short duration of follow-up. Many of the recruited patients had moderate to severe renal failure (CKD Stage 3b or above). The relation between urinary mtDNA level, intra-renal scarring and renal function deterioration in early stages of DN require further studies.
In our study, all recruited patients had biopsy-proven DN. The advantage of this strategy is that other unrelated causes of renal impairment or proteinuria, which are very common in diabetic patients [36] , are excluded. In addition, we can study directly the correlation of mtDNA levels between urine and kidney tissue, as well as their relation with intra-renal scarring. On the other hand, the recruitment of only biopsy-confirmed DN may introduce sampling bias in our study population because most patients with DN do not require renal biopsy, and it is usually patients with atypical features (e.g. short duration of diabetes, absence of retinopathy or presence of microscopic hematuria) that end up undergoing biopsy.
In conclusion, our study shows that mtDNA is readily detectable in urinary supernatant and kidney tissue, and its levels correlate with renal function and scarring in DN. Further studies are needed to determine the accuracy of urinary supernatant mtDNA level as a prognostic indicator of DN, as well as its role in other kidney diseases.
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